Long-term results of combined-modality therapy for inflammatory breast carcinoma

Clinical Breast Cancer

Volumn 5, Issue 5, 2004, Pages 358-363

  Baldini, Editta ^a   Gardin, Giovanni ^b   Evangelista, Giuseppe ^a   Prochilo, Tiziana ^a   Collecchi, Paola ^c   Lionetto, Rita ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

5 Fluorouracil; Colony stimulating factors; Cyclophosphamide; Integrated treatment; Prognostic factors; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLA; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 12144255402     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.042     Document Type: Article

References (17)

1. Lucas F, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer 1978; 41:1595-1605.
2. Levine P, Steinhorn S, Ries L. Inflammatory breast cancer. The experience of the Surveillance Epidemiology and End Results (SEER) Program. J Natl Cancer Inst 1985; 74:291-297.
3. Jaiyesimi AI, Budzar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-1024.
4. Thoms W, McNeese M, Fletcher G. Multimodal treatment for inflammatory breast cancer. J Int Radiat Oncol Biol Phys 1989; 17:739-745.
5. Maloisel F, Doufour P, Bergerat J, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65:851-855.
6. Haagensen CD. Disease of the breast. Philadelphia: WB Saunders; 1971:560-584.
7. Baldini E, Gardin G, Giannessi PG, et al. A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. Tumori 1997; 83:829-833.
8. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard CEF/CMF: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003; 14:227-232.
9. Kaplan EL, Meier P, Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
10. McBride CM, Hortobagyi GN. Primary inflammatory carcinoma of the female breast: staging and treatment possibilities. Surgery 1985; 98:792-797
11. Chauvergne J, Durand M, Richaud P, et al. Traitement combiné des cancers mammaires localisées à haute risque mètastatique: resultats d'une, ètude prospective controlée. J Gynecol Obstet Biol Reprod 1981; 10:75-85.
12. Pouillard P, Palangie T, Jouve M. Cancer inflammatoire du sein traitèe par une association de chèmiotherapie e d'irradiation. Bull Cancer 1981; 68:171-176.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. J Natl Cancer Inst 2001; 11:783-792.
14. Zylberg B, Salat Baroux J, Ravina JH. Initial chemotherapy in inflammatory carcinoma of the breast. Cancer 1982; 49:1537-1543.
15. Kueuer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
16. Merajever SD, Weber BC, Cody R, et al. Breast conservation and prolonged chemotherapy fro locally advanced breast cancer: summation dose-intensity. J Clin Oncol 1997; 15:2873-2881.
17. von Minckwitz G, Raab G, Blohmer JU, et al. Primary chemotherapy adapted on in vivo chemosensitivity in patients with primary breast cancer: the pilot GEPARTRIO study. Proc Am Soc Clin Oncol 2003; 23:22 (Abstract #85).